JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Arcus Biosciences Inc

Закрыт

СекторЗдравоохранение

16.76 0.96

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

16.4

Макс.

16.95

Ключевые показатели

By Trading Economics

Продажи

132M

160M

Сотрудники

627

EBITDA

126M

4M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+79.11% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

882M

1.9B

Предыдущая цена открытия

15.8

Предыдущая цена закрытия

16.76

Техническая оценка

By Trading Central

Уверенность

Neutral Evidence

Arcus Biosciences Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 окт. 2025 г., 20:49 UTC

Отчет

Correction to Thermo Fisher Article on Oct. 22

23 окт. 2025 г., 23:51 UTC

Обсуждения рынка

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 окт. 2025 г., 23:49 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

23 окт. 2025 г., 23:49 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 окт. 2025 г., 23:37 UTC

Обсуждения рынка

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 окт. 2025 г., 22:58 UTC

Обсуждения рынка

Global Energy Roundup: Market Talk

23 окт. 2025 г., 22:57 UTC

Обсуждения рынка

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 окт. 2025 г., 22:49 UTC

Приобретения, слияния, поглощения

How Trump Sparked a New Era of State Capitalism -2-

23 окт. 2025 г., 22:49 UTC

Приобретения, слияния, поглощения

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 окт. 2025 г., 22:17 UTC

Отчет

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 окт. 2025 г., 21:41 UTC

Отчет

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 окт. 2025 г., 21:05 UTC

Отчет

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

23 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Отчет

Auto & Transport Roundup: Market Talk

23 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

23 окт. 2025 г., 20:35 UTC

Отчет

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 окт. 2025 г., 20:28 UTC

Отчет

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 окт. 2025 г., 20:15 UTC

Обсуждения рынка
Отчет

Global Commodities Roundup: Market Talk

23 окт. 2025 г., 20:10 UTC

Отчет

Newmont Mining 3Q Adj EPS $1.71

23 окт. 2025 г., 20:10 UTC

Отчет

Newmont Mining 3Q Sales $5.52B

23 окт. 2025 г., 20:10 UTC

Отчет

Newmont Mining 3Q EPS $1.67

23 окт. 2025 г., 20:09 UTC

Отчет

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 окт. 2025 г., 20:07 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

23 окт. 2025 г., 20:07 UTC

Обсуждения рынка
Отчет

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 окт. 2025 г., 20:07 UTC

Отчет

Blackstone Looks to IPOs for Investment Exits -- Update

23 окт. 2025 г., 20:05 UTC

Отчет

Intel 3Q Gross Margin 38.2% >INTC

23 окт. 2025 г., 20:04 UTC

Отчет

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 окт. 2025 г., 20:04 UTC

Отчет

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 окт. 2025 г., 20:04 UTC

Отчет

Intel: 4Q Guidance Excludes Altera >INTC

23 окт. 2025 г., 20:04 UTC

Отчет

Intel Sees 4Q Adj EPS 8c >INTC

Сравнение c конкурентами

Изменение цены

Arcus Biosciences Inc Прогноз

Целевая цена

By TipRanks

79.11% рост

Прогноз на 12 месяцев

Средняя 32.33 USD  79.11%

Максимум 54 USD

Минимум 14 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для Arcus Biosciences Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

12 ratings

11

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

8.01 / 8.75Поддержка и Сопротивление

Краткосрочная

Neutral Evidence

Среднесрочная

Neutral Evidence

Долгосрочная

Weak Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat